Tau PET Imaging in Atypical Dementias
Phase 1
Active, not recruiting
- Conditions
- Primary Progressive Aphasia With Suspected Alzheimer's Disease
- Interventions
- Drug: 18F-AV-1451Device: PET
- Registration Number
- NCT03283449
- Lead Sponsor
- University of Chicago
- Brief Summary
The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
- Must have primary progressive aphasia
Read More
Exclusion Criteria
- Pregnancy
- Breastfeeding
- Receiving radiation clinically
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description AV-1451 Recipients 18F-AV-1451 Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging. AV-1451 Recipients PET Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging.
- Primary Outcome Measures
Name Time Method Tau levels in PPA participants 2 years Tau deposition as measured by 18F-AV-1451 standardized uptake value ratio (SUVR) in cortical and medial temporal regions.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Chicago - American School Building
🇺🇸Chicago, Illinois, United States